JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB142853

Cerivastatin sodium, HMG-CoA reductase inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 481.5 Da, Purity >98%. Potent HMG-CoA reductase inhibitor (Ki = 13 nM). Shows higher potency than Lovastatin (ab120614). Enantiomerically pure pyridine derivative. Reduces plasma cholesterol levels in vivo. Orally active.
1 Images
Chemical Structure - Cerivastatin sodium, HMG-CoA reductase inhibitor (AB142853)
  • Chemical Structure

Lab

Chemical Structure - Cerivastatin sodium, HMG-CoA reductase inhibitor (AB142853)

2D chemical structure image of ab142853, Cerivastatin sodium, HMG-CoA reductase inhibitor

Key facts

CAS number

143201-11-0

Purity

>98%

Form

Solid

form

Molecular weight

481.5 Da

Molecular formula

C<sub>2</sub><sub>6</sub>H<sub>3</sub><sub>3</sub>FNNaO<sub>5</sub>

PubChem

23663992

Nature

Synthetic

Solubility

Soluble in water

Biochemical name

Cerivastatin sodium

Biological description

Potent HMG-CoA reductase inhibitor (Ki = 13 nM). Shows higher potency than Lovastatin (ab120614). Enantiomerically pure pyridine derivative. Reduces plasma cholesterol levels in vivo. Orally active.

Canonical smiles

CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)[O-])O)O.[Na+]

Isomeric smiles

CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O.[Na+]

InChi

InChI=1S/C26H34FNO5.Na/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);/q;+1/p-1/b11-10+;/t19-,20-;/m1./s1

InChiKey

GPUADMRJQVPIAS-QCVDVZFFSA-M

IUPAC Name

sodium;(E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoate

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Proceedings of the National Academy of Sciences of the United States of America 120:e2217831120 PubMed36745799

2023

Limb girdle muscular disease caused by mutation and statin myopathy treatable with mevalonolactone.

Applications

Unspecified application

Species

Unspecified reactive species

Yuval Yogev,Zamir Shorer,Arie Koifman,Ohad Wormser,Max Drabkin,Daniel Halperin,Vadim Dolgin,Regina Proskorovski-Ohayon,Noam Hadar,Geula Davidov,Hila Nudelman,Raz Zarivach,Ilan Shelef,Yonatan Perez,Ohad S Birk

Cell reports 37:110056 PubMed34818551

2021

Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis.

Applications

Unspecified application

Species

Unspecified reactive species

Madeleine Dorsch,Manuela Kowalczyk,Mélanie Planque,Geronimo Heilmann,Sebastian Urban,Philip Dujardin,Jan Forster,Kristina Ueffing,Silke Nothdurft,Sebastian Oeck,Annika Paul,Sven T Liffers,Farnusch Kaschani,Markus Kaiser,Alexander Schramm,Jens T Siveke,Monte M Winslow,Sarah-Maria Fendt,Perihan Nalbant,Barbara M Grüner

Cell reports 27:1265-1276.e4 PubMed31018139

2019

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yoshimasa Saito,Toshihide Muramatsu,Yae Kanai,Hidenori Ojima,Aoi Sukeda,Nobuyoshi Hiraoka,Eri Arai,Yuko Sugiyama,Juntaro Matsuzaki,Ryoei Uchida,Nao Yoshikawa,Ryo Furukawa,Hidetsugu Saito
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com